Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction: Adopting machine learning to predict breast cancer patients adherence with lifestyle recommendations and quality of life outcomes.

Frontiers in digital health·2026

Same author

YY1 in four dimensions: From context-dependent transcription factor to spatiotemporal gene regulator.

Biochimica et biophysica acta. Reviews on cancer·2026

Same author

Healthful and Unhealthful Plant-Based Diets and Their Association with Cardiometabolic Targets in Women Diagnosed with Breast Cancer: A Cross-Sectional Analysis of a Lifestyle Trial.

Nutrients·2025

Same author

Role of microRNAs in the regulation of RKIP and signaling pathways in cancer.

Biochimica et biophysica acta. Reviews on cancer·2025

Same author

Adopting machine learning to predict breast cancer patients adherence with lifestyle recommendations and quality of life outcomes.

Frontiers in digital health·2025

Same author

RNA-based drugs: current, imminent and possible therapeutic applications.

Pharmacology & therapeutics·2025

Search research articles

Related Experiment Video

Updated: Jun 5, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Understanding rituximab function and resistance: implications for tailored therapy.

Alfredo Amoroso¹, Sameh Hafsi, Loredana Militello

¹Department of Biomedical Sciences, University of Catania, Catania, Italy.

Frontiers in Bioscience (Landmark Edition)

|January 4, 2011

Summary

This summary is machine-generated.

Rituximab improves B-cell lymphoma survival but resistance occurs. Understanding its molecular functions, including direct and indirect cell death induction, can help overcome resistance and develop new therapies.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Experiment Videos

Last Updated: Jun 5, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Area of Science:

Immunology
Oncology
Molecular Biology

Background:

Anti-CD20 monoclonal antibody (rituximab) enhances chemotherapy efficacy in B-cell lymphoma.
Patient relapse after rituximab treatment necessitates understanding its molecular mechanisms and resistance pathways.

Purpose of the Study:

To elucidate the molecular functions of rituximab in B-cell lymphoma treatment.
To explore direct and indirect mechanisms of rituximab-induced cell death.
To identify strategies for overcoming rituximab resistance.

Main Methods:

Analysis of existing research on rituximab's role as a signal-inducing and chemosensitizing agent.
Review of studies on direct mechanisms (growth inhibition, apoptosis, chemosensitization) and indirect mechanisms (complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity).
Examination of rituximab resistance mechanisms and cellular target modifications post-treatment.

Main Results:

Rituximab induces B-cell death through direct effects like apoptosis and indirect effects like CDC and ADCC.
Rituximab acts as a chemosensitizing agent by negatively regulating survival pathways.
Cellular targets can be modified after rituximab treatment, offering potential for novel therapeutic strategies.

Conclusions:

Understanding rituximab's molecular mechanisms is crucial for overcoming treatment resistance in B-cell lymphoma.
Modified cellular targets post-rituximab therapy may represent new avenues for treating resistant cases.
Further research into rituximab's functions can lead to improved therapeutic strategies for lymphoma patients.